首頁 > 市場調查報告書 > 製藥

眼科藥物

全球視網膜疾病藥物市場 (2022-2028)：按類型、劑型和分銷渠道分列的規模、份額、增長分析和預測

市場調查報告書

商品編碼

1270798

全球視網膜疾病藥物市場 (2022-2028)：按類型、劑型和分銷渠道分列的規模、份額、增長分析和預測

Global Retinal Disease Therapeutics Market Size, Share, Growth Analysis, By Type, By Dosage forms, By Distribution Channel - Industry Forecast 2022-2028

出版日期: 2023年04月11日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

視網膜疾病藥物市場規模2021年將達到114.9億美元，2022年將達到125.7億美元，2023年至2030年預測期內復合年增長率為9.3%，預計2030年將增長至256.9億美元.

全球有超過 2.53 億人患有視網膜疾病，預計這將在未來幾年對醫療保健行業造成重大經濟負擔。此外，由於81%的視障患者年齡在50歲以上，預期壽命的增加也將給眼科醫療行業帶來沉重負擔。由於糖尿病在新興國家的流行，包括糖尿病性視網膜病變、糖尿病性黃斑水腫等在內的視網膜疾病病例不斷增加。未來，全球範圍內專門治療視網膜疾病的專家數量將增加，有望推動市場的擴張。此外，到 2028 年底，許多國家收緊昂貴的視網膜疾病治療報銷政策也有望支持市場擴張。

在本報告中，我們調查了全球視網膜疾病藥物市場，並提供了市場概況、市場各種影響因素分析、技術和創新趨勢、市場規模的轉變和預測，總結了細分，競爭格局、主要公司概況等。

內容

執行摘要

市場概覽

母市場分析

市場概覽

市場規模

市場動態
司機
機會
約束因素
任務
SWOT 分析

主要市場洞察

技術分析
價格分析
供應鏈分析
價值鏈分析
市場生態系統
知識產權分析
貿易分析
啟動分析
原材料分析
創新矩陣
管道產品分析
宏觀經濟指標

COVID-19 的影響

經濟影響：情景評估
修訂市場規模
COVID-19 對主要細分市場的影響
企業 COVID-19 戰略

市場動態和前景

市場動態
司機
機會
約束因素
任務
監管狀況
SWOT 分析
波特的分析
Skyquest 對未來顛覆的特別洞察
全球視網膜疾病藥物市場：按類型分類
黃斑變性
糖尿病視網膜病變
其他
全球視網膜疾病藥物市場：按配方分類
凝膠
我的解決方案
膠囊劑和片劑
眼藥水
藥膏
全球視網膜疾病藥物市場：按分銷渠道分類
醫院藥房
在線藥店
零售藥房

按地區劃分的市場規模

北美
美國
加拿大
歐洲
德國
西班牙
法國
英國
其他歐洲地區
亞太地區
中國
印度
日本
韓國
亞太其他地區
拉丁美洲
巴西
其他拉丁美洲地區
中東和非洲
海灣合作委員會國家
南非
其他中東和非洲地區

主要公司簡介

競爭格局
目標公司數量
主要公司的定位
主要公司的市場份額
Merck and Co., Inc.
Novartis AG
Allergan plc
F. Hoffmann-La Roche AG
Regeneron Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
Shire（Takeda Pharmaceutical Company Limited）
Bayer AG
Graybug Vision, Inc.
Acucela Inc.（Kubota Pharmaceutical Holdings Co., Ltd.）.

簡介目錄

Product Code: SQMG35H2021

Global Retinal Disease Therapeutics Market size was valued at USD 11.49 billion in 2021 and is poised to grow from USD 12.57 billion in 2022 to USD 25.69 billion by 2030, growing at a CAGR of 9.3% in the forecast period (2023-2030).

Over 253 million individuals worldwide suffer from retinal abnormalities, which are a rising problem in both developed and developing countries and are predicted to put a considerable financial burden on the healthcare industry in the years to come. The rising life expectancy of the population is expected to put significant strain on the ophthalmic care industry, as 81 percent of patients with vision impairment are over 50. Because diabetes is more common in emerging nations, there are more cases of retinal diseases including diabetic retinopathy, diabetic macular edoema, etc. As more qualified professionals that specialise in the treatment of retinal illnesses become available globally over the course of the projected period, the market is anticipated to grow. Additionally, it is anticipated that by the end of 2028, enhanced reimbursement policies in numerous countries for the pricey treatment of retinal disorders will support market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of global Retinal Disease Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Segments covered in this report

Global retinal disease therapeutics market is segmented based on type, dosage form, distribution channel, and region. Based on type, the market is divided into macular degeneration, diabetic retinopathy and others. Based on dosage form, the global market is segmented into gels, eye solutions, capsules & tablets, eye drops, ointments. Based on distribution channel, the market is segmented into hospital pharmacy, online pharmacy, retail pharmacy. Based on region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and MEA.

Driver

An increase in the prevalence of eye disorders

The global market for retinal pharmaceuticals will be driven by the increased prevalence of eye-related disorders, particularly in industrialised nations. In 2016, 4.2 million Americans were among the 93 million people globally who have diabetic retinopathy, according to a report from the American Academy of Ophthalmology. By 2040, there will be 14.9 to 21.5 million early AMD cases and 3.9 to 4.8 million late AMD cases in Europe, predicts the NCBI. Growth in the worldwide retinal disease therapeutics market is anticipated to be driven by rising health education initiatives on eye disorders to encourage early treatment and prevent visual damage in emerging regions.

Growing Awareness Programmes for Retinal Diseases

To increase awareness of the diagnosis and available treatments for retinal diseases, several campaigns have been created internationally. The International Centre for Eye Health's goal is to increase public awareness of problems with eye health and accessible remedies. The World Glaucoma Association has been hosting the World Glaucoma Congress for the past six years to encourage discussion of new glaucoma treatments. To increase the use of age-related macular degeneration (AMD) treatments, the Macular Degeneration Association, Inc. holds seminars every month in a number of places. The rise of the retinal disease therapeutics market is anticipated to be fueled by these efforts' expected promotion of the use of various treatment modalities.

Restraint

The cost of treating retinal diseases is more expensive.

The high cost of retinal treatment techniques, patient complaints of short-term side effects, and long-term implications including infection and inflammation after laser eye surgery may all hinder the growth of the global market. Furthermore, dangers like accidental scleral perforation may occur during surgical procedures like pneumatic retinopexy, which could affect patient preferences and impede the expansion of the global market. The market for medicines for retinal diseases is also being hampered by the inadequate healthcare infrastructure in emerging nations.

Market Trends

High-End Technology Development to Support Market Development

Inherited retinal illnesses are frequently treated with retinal gene therapy. Gene therapy can treat vision impairment caused by the RPE65 gene mutation. Luxturna is a recently created gene therapy used to treat people with type 2 Leber's congenital amaurosis. It is a genetic disorder that affects vision from birth and causes a deterioration that progresses rapidly. Recombinant viruses are used in numerous retinal gene treatments that are now undergoing clinical trials. This aspect is anticipated to increase the market for therapies for retinal diseases globally between 2022 and 2028, the study period.

Executive Summary

Market overview

Exhibit: Executive Summary - Chart on Market Overview
Exhibit: Executive Summary - Data Table on Market Overview
Exhibit: Executive Summary - Chart on Global Global retinal disease therapeutics market Characteristics
Exhibit: Executive Summary - Chart on Market by Geography
Exhibit: Executive Summary - Chart on Market Segmentation
Exhibit: Executive Summary - Chart on Incremental Growth
Exhibit: Executive Summary - Data Table on Incremental Growth
Exhibit: Executive Summary - Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

Market Dynamics
Exhibit: Impact analysis of DROC, 2021
Drivers
Opportunities
Restraints
Challenges
SWOT Analysis

KEY MARKET INSIGHTS

Technology Analysis
(Exhibit: Data Table: Name of technology and details)
Pricing Analysis
(Exhibit: Data Table: Name of technology and pricing details)
Supply Chain Analysis
(Exhibit: Detailed Supply Chain Presentation)
Value Chain Analysis
(Exhibit: Detailed Value Chain Presentation)
Ecosystem Of the Market
Exhibit: Parent Market Ecosystem Market Analysis
Exhibit: Market Characteristics of Parent Market
IP Analysis
(Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
Trade Analysis
(Exhibit: Data Table: Import and Export data details)
Startup Analysis
(Exhibit: Data Table: Emerging startups details)
Raw Material Analysis
(Exhibit: Data Table: Mapping of key raw materials)
Innovation Matrix
(Exhibit: Positioning Matrix: Mapping of new and existing technologies)
Pipeline product Analysis
(Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
Macroeconomic Indicators

COVID IMPACT

Introduction
Impact On Economy-scenario Assessment
Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
Revised Market Size
Exhibit: Data Table on Global Global retinal disease therapeutics market size and forecast 2021-2027 ($ million)
Impact Of COVID On Key Segments
Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
COVID Strategies By Company
Exhibit: Analysis on key strategies adopted by companies